Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective

Table 4 Model results: base case

Deterministic	TIO/OLO	UMEC/VI	Difference
Average number of exacerbations, per patient per life-year
Severe	0.074	0.070	−0.004
Total (moderate and severe)	0.589	0.575	−0.014
Outcomes at end of 3 years
Survival at end of time horizon	89.9%	90.3%	0.4%
Undiscounted Lys	2.870	2.874	0.004
Discounted (3% p.a.) QALY	2.118	2.147	0.029
Costs at end of 3 years
Drug costs	€2820	€2490	−€335
Non-drug costs	€3210	€3160	−€58
Exacerbation event costs	€1020	€973	−€47
Health state costs (by dyspnea severity)	€2190	€2180	−€10
Total costs	€6040	€5640	−€393
Incremental results (versus TIO/OLO)
ICER (€ per QALY gained)		Dominant
ICER (€ per LY gained)		Dominant

Cost and cost-effectiveness data are presented to three significant figures for values of four figures or more, and to the nearest Euro for values of three figures or less
ICER incremental cost-effectiveness ratio, LY life years, QALY quality-adjusted life-year, p.a. per annum, TIO/OLO tiotropium/olodaterol, UMEC/VI umeclidinium/vilanterol

ISSN: 1465-993X